Morepen Labs Q3 profits grow by 120% to 23.8 crore
Firm sets eyes on multi-billion dollar global API (Active Pharmaceutical Ingredients) market with the addition of new molecules12-02-2021
12-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that subsequent to the declaration of unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December, 2020, the Company is organizing an 'Investors and Analyst Conference Call' on Thursday, 18th February, 2021 at 1.00 P.M. (IST).12-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed the Investors Presentation (Q3'FY21) February 2021, based on the financial performance of the Company for the Quarter and Nine months ended 31st December, 2020.12-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed the press release on the financial performance of the Company for the Quarter and Nine Months ended 31st December, 2020 with the title - 'Morepen Labs eyeing multi-billion dollar global market for new API molecules going off-patent in next 5-6 years'12-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31St December, 2020
This is to inform you that the Board of Directors of the Company, in their meeting held on Friday, 12th February, 2021 (commenced at 12.15 P.M. and concluded at 2.00 P.M.), have, inter-alia, considered and approved the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31st December, 2020. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, a copy of the 'Results' along-with Limited Review Report of the Statutory Auditors of the Company, are enclosed herewith.12-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Outcome Of The Board Meeting
This is to inform you that the Board of Directors of the Company, in their meeting held on Friday, 12th February, 2021 (commenced at 12.15 P.M. and concluded at 2.00 P.M.), have, inter-alia, considered and approved the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31st December, 2020. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, a copy of the 'Results' along-with Limited Review Report of the Statutory Auditors of the Company, are enclosed herewith.12-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Morepen Laboratories Ltd has informed BSE regarding loss of Share Certificates09-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Board Meeting Intimation for Approval Of The Un-Audited Financial Results For The Quarter And Nine Months Ended December, 2020
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2021 ,inter alia, to consider and approve the Un-audited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2020.05-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Morepen Laboratories Ltd has informed BSE regarding loss of Share Certificates02-02-2021
MOREPEN LABORATORIES LTD. - 500288 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Morepen Laboratories Ltd has informed BSE regarding issuance of duplicate share Certificates29-01-2021